CD19 and lymphoma: The percentage of anti-CD19 CAR T-cells detected by biotinylated anti-Whitlow mAb from lymphoma patients treated with Brexu-cel, Liso-cel, and Axi-cel was comparable to that obtained with CD19 antigen-based CAR detection assays (96 ± 2%; 96 ± 4%; and 87 ± 15%; respectively) (Figure 2B).